Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Lipocine Inc. (LPCN)
Last lipocine inc. earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.lipocine.com
Company Research
Source: Yahoo! Finance
More than half of planned participants have completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation reported Topline results are on track for the second quarter of 2026 SALT LAKE CITY Nov. 18, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD. This was the first of two DSMB reviews planned during the study and conducted after approximately one-third of planned 80 participants completed at least the day seven follow-up visit (n=30). The DSMB recommended that the trial continue as planned without modification. (PRNewsfoto/Lipocine Inc.) 47 participants have completed dos
Show less
Read more
Impact Snapshot
Event Time:
LPCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPCN alerts
High impacting Lipocine Inc. news events
Weekly update
A roundup of the hottest topics
LPCN
News
- Lipocine (NASDAQ:LPCN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PR Newswire
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]Yahoo! Finance
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)PR Newswire
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]Yahoo! Finance
LPCN
Analyst Actions
- 1/21/26 - HC Wainwright
LPCN
Sec Filings
- 1/20/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/12/26 - Form 8-K
- LPCN's page on the SEC website